Chiara Mannelli
Biographic Data
| ID | 4620401 |
|---|---|
| NAME | Chiara Mannelli |
| GIVEN NAMES | Chiara |
| FAMILY NAME | Mannelli |
| SIGNATURE | MANNELLI C |
| AFFILIATIONS | Istituto Superiore di Sanità |
| ORCID | 0000-0003-3488-4441 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
What if all participants get the same treatment? An ethical perspective on single arm trials
Randomised controlled trials have traditionally been considered the gold standard for evidence on the efficacy of new treatments. However, applications to marketing authorisation are increasingly based on data stemming from single arm trials (SATs), which do not randomise to a control arm and in which all patients receive the treatment under study. This has generated debate over the characteristics and methodological limitations of SATs and the a…
Who decides who goes first? Taking democracy seriously in micro-allocative healthcare decisions
The structural scarcity of healthcare resources has deeply challenged their fair distribution, prompting the need for allocation criteria. Long under the spotlight of the bioethical debate with an extraordinary peak during the recent COVID-19 pandemic, micro-allocation of healthcare has been extensively discussed in the literature with regard to issues of substantive and formal justice. This paper addresses a relatively underdiscussed question wi…
Decentralized clinical trials (DCTs)
Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of …
Whose life to save? Scarce resources allocation in the Covid-19 outbreak
After initially emerging in China, the coronavirus (COVID-19) outbreak has advanced rapidly. The World Health Organization (WHO) has recently declared it a pandemic, with Europe becoming its new epicentre. Italy has so far been the most severely hit European country and demand for critical care in the northern region currently exceeds its supply. This raises significant ethical concerns, among which is the allocation of scarce resources. Professi…
No prominent works on this page.
Whose life to save? Scarce resources allocation in the Covid-19 outbreak
After initially emerging in China, the coronavirus (COVID-19) outbreak has advanced rapidly. The World Health Organization (WHO) has recently declared it a pandemic, with Europe becoming its new epicentre. Italy has so far been the most severely hit European country and demand for critical care in the northern region currently exceeds its supply. This raises significant ethical concerns, among which is the allocation of scarce resources. Professi…
Decentralized clinical trials (DCTs)
Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of …
Who decides who goes first? Taking democracy seriously in micro-allocative healthcare decisions
The structural scarcity of healthcare resources has deeply challenged their fair distribution, prompting the need for allocation criteria. Long under the spotlight of the bioethical debate with an extraordinary peak during the recent COVID-19 pandemic, micro-allocation of healthcare has been extensively discussed in the literature with regard to issues of substantive and formal justice. This paper addresses a relatively underdiscussed question wi…
What if all participants get the same treatment? An ethical perspective on single arm trials
Randomised controlled trials have traditionally been considered the gold standard for evidence on the efficacy of new treatments. However, applications to marketing authorisation are increasingly based on data stemming from single arm trials (SATs), which do not randomise to a control arm and in which all patients receive the treatment under study. This has generated debate over the characteristics and methodological limitations of SATs and the a…
Economics (3 works) · Law (3 works) · Medicine (3 works) · Political science (3 works) · Computer Science (2 works) · Engineering (2 works) · Ethics in medical practice (2 works) · Health care (2 works) · Resource allocation (2 works) · Scarcity (2 works)